ABLYNX ANNOUNCES EXTENSION OF ION CHANNEL RESEARCH COLLABORATION WITH
MERCK & CO., INC.

GHENT, Belgium, 26 March 2015 – Ablynx [Euronext Brussels: ABLX; OTC: ABYLY] today announced an
extension of its initial two-year research collaboration with Merck & Co., Inc., known as MSD outside the
United States and Canada, to develop and commercialise Nanobody® candidates directed towards an
undisclosed voltage gated ion channel.

Merck & Co., Inc. will extend their funding of the research collaboration with Ablynx to the end of
September 2016. This ion channel collaboration was announced in October 2012 and included a €6.5
million upfront payment and €2 million in initial research funding.

Merck and Ablynx have a separate collaboration in the field of cancer immuno-therapy, announced in
February in 2014, with a €20 million upfront payment, €10.7 million in research funding and total
potential milestone payments of up to €1.7 billion plus royalties.

Commenting on the announcement, Dr Edwin Moses, CEO of Ablynx, said:
“We are pleased to extend the research funding for our current ion channel collaboration with Merck.
To date, we have made encouraging progress in the discovery of Nanobodies against this very
challenging target and the extension will potentially allow us to build on these advances.”

As part of its hybrid model of developing its wholly-owned assets and partnering some programmes,
Ablynx has research and development collaborations with multiple pharmaceutical companies including
AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co., Inc., Merck Serono and Novartis involving
more than 20 active therapeutic programmes and which have already generated more than €340 million
in non-dilutive cash for the Company.

About the ion channel collaboration between Ablynx and Merck & Co., Inc.
In October 2012, Ablynx and a subsidiary of Merck & Co entered into a collaboration to develop and
commercialise Nanobody candidates directed towards a voltage gated ion channel, with the option to
develop and commercialise a Nanobody to a second target. Under the terms of the agreement, Merck
gains exclusive global rights to Nanobodies against the selected target, with an option for similar rights
to a second target. Upon signing, Merck paid Ablynx a €6.5 million upfront payment. In addition, Ablynx
is eligible to receive research funding and up to €448 million in research, regulatory and commercial
milestone payments associated with the progress of multiple candidates, as well as tiered royalties on
any products derived from the collaboration. Ablynx is responsible for the discovery of Nanobody
candidates and Merck is responsible for the research, development, manufacturing and
commercialisation of any Nanobody product resulting from the collaboration.

About Ablynx
Ablynx is a biopharmaceutical company engaged in the development of Nanobodies®, proprietary
therapeutic proteins based on single-domain antibody fragments, which combine the advantages of
conventional antibody drugs with some of the features of small-molecule drugs. Ablynx is dedicated to
creating new medicines which will make a real difference to society. Today, the Company has more than 30 proprietary and partnered programmes in development in various therapeutic areas including inflammation, haematology, oncology and respiratory disease. The Company has collaborations with multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim, Eddingpharm, Merck & Co. Inc., Merck Serono and Novartis. The Company is headquartered in Ghent, Belgium. More information can be found on www.ablynx.com.

For more information, please contact:

Ablynx:
Dr Edwin Moses CEO
t: +32 (0)9 262 00 07 m: +32 (0)473 39 50 68 e: edwin.moses@ablynx.com
Marieke Vermeersch Associate Director Investor Relations
t: +32 (0)9 262 00 82 m: +32 (0)479 49 06 03 e: marieke.vermeersch@ablynx.com

Ablynx media relations Consilium Strategic Communications:
Mary-Jane Elliott, Jonathan Birt, Chris Welsh, Lindsey Neville
t: +44 203 709 5700 e: ablynx@consilium-comms.com

Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company or, as appropriate, the Company directors’ current expectations and projections about future events. By their nature, forward-looking statements involve a number of risks, uncertainties and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result, the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its parent or subsidiary undertakings or any such person’s officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.